New test for detection of lung cancer

Perceptronix Medical Inc has recently announced that it has unblinded its clinical trial for the ClearSign Test, a non-invasive test for the detection of lung cancer based on the automated cytometric analysis of sputum. In this test lung cancer is detected by a non-invasive test. The company has unblended the test after meeting all the significant objectives of the trial. The company is looking forward to getting the licenses for the ClearSign Test by early 2006.

The success of this clinical trial was very important for Perceptronix. Researchers have worked hard for several years for developing an effective non-invasive detection test for lung cancer, which could be implemented easily. The key step in acquiring this goal is the result from this clinical trial and will be provided as the basis for the application of license. If this is approved then marketing of the test in Canada, the European Union and several other countries could be made possible.

The product Manager of ClearSign Dr. Roger Kemp hopes that the ClearSign Test would be widely made available for detecting lung cancer in its earliest stages.

The ClearSign Test clinical trial was performed at nine places in Canada, the US, the EU and Korean which over 1200 lung cancer patients were involved.

Once the licensing applications are filed reports would be made on the details about the performance of the clinical trial of the test.

The patients of lung cancer have a poor survival rate. The five-year survival is found to be less than 15%. The reason for the poor survival rate is because the symptoms of this disease in its early stage is not easily detectable and so it is not possible for the diagnosis to be made until the disease reaches its advanced stage. Lung cancer is considered to be the greatest cancer killer amongst both the sexes. It is believed by Perceptronix that the key to improve outcomes for the patients of lung cancer is to detect it at its early stage.

At present, no test for the detection of lung cancer in its initial stage is available.

Did you know?
Perceptronix Medical Inc has recently announced that it has unblinded its clinical trial for the ClearSign Test, a non-invasive test for the detection of lung cancer based on the automated cytometric analysis of sputum. In this test lung cancer is detected by a non-invasive test. The company has unblended the test after meeting all the significant objectives of the trial. The company is looking forward to getting the licenses for the ClearSign Test by early 2006.